UroGen Pharma Ltd. Ordinary Shares
URGN Real Time Price USDRecent trades of URGN by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in URGN holdings by institutional investors
Quarterly net insider trading by URGN's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$30,000 Jul 20, 2026 Issue: None
-
$30,000 Apr 20, 2026 Issue: None
-
$30,000 Jan 20, 2026 Issue: None
-
$30,000 Oct 20, 2025 Issue: None
-
$30,000 Jul 21, 2025 Issue: None
-
$30,000 Apr 21, 2025 Issue: None
-
$30,000 Jan 20, 2025 Issue: None
-
$30,000 Oct 21, 2024 Issue: Health Issues
-
$30,000 Jan 22, 2024 Issue: Health Issues
-
$30,000 Oct 20, 2023 Issue: Health Issues
-
$30,000 Jul 20, 2023 Issue: Health Issues
-
$60,000 Jan 20, 2023 Issue: Health Issues
-
$60,000 Oct 20, 2022 Issue: Health Issues
-
$20,000 Jul 20, 2022 Issue: Health Issues
-
$40,000 Jul 18, 2022 Issue: Health Issues
-
$40,000 Apr 15, 2022 Issue: Health Issues
-
$40,000 Jan 15, 2022 Issue: Health Issues
-
$40,000 Oct 18, 2021 Issue: Health Issues
-
$40,000 Jul 16, 2021 Issue: Health Issues
-
$40,000 Apr 17, 2021 Issue: Health Issues
-
$40,000 Jan 15, 2021 Issue: Health Issues
-
$40,000 Oct 19, 2020 Issue: Health Issues
-
$40,000 Jul 12, 2020 Issue: Health Issues
-
$40,000 Apr 20, 2020 Issue: Health Issues
Former government officials who have lobbied for URGN
7 former government officials from 6 congressional offices at 2 lobbying firms have lobbied for URGN, most recently Oct 21, 2024.
-
Robert Wood House Chief of Staff to HHS Secretary; Intern to Rep. Scott Klug -
Daniel Farmer House Intern, Staff Asst, Leg. Corr./Leg. Asst. for Rep. Debbie Wasserman Schultz; Leg. Asst., Sr. Leg. Asst., Leg. Dir. for Zack Space -
Robb Walton Senate Senior Health Policy Advisor and Counsel Sen Cassidy; Advisor Rep. Cassidy; Research Asst., Staff Asst., Intern on Senate HELP, Ranking Member, Sen. Enzi; Intern to Rep. Nunes -
Remy Mason Senate Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren; Intern to Rep. Allyson Schwartz -
Tyler Thompson Senate New Legislative Assistant, Sen. Johnny Isakson, 2005-2012; Legislative Correspondent, Sen. Saxby Chambliss, 2005; Legislative Correspondent, Sen. Zell Miller, 2002-2005. -
Chris Jones House New Chief of Staff, Rep. Mike Ferguson, 2001-2009; Deputy Chief of Staff, Rep. David McIntosh, 1995-2001; Communications Director, House Government Reform and Oversight Subcommittee, 1996-2001; Press Secretary, Rep. John Myers, 1994-1995. -
Adam Higgins House New Legislative Assistant, Rep. Mike Ferguson, 2007-2008.
URGN Estimated quarterly lobbying spending
URGN Revenue by Segment or Geography
New URGN patent grants
-
Patent Title: Treatment of low-grade intermediate-risk non-muscle-invasive bladder cancer with a thermally gelling pharmaceutical composition containing mitomycin Sep. 22, 2026
-
Patent Title: Material and method for treating internal cavities Oct. 14, 2025
-
Patent Title: Material and method for treating cancer Jun. 24, 2025
-
Patent Title: Material and method for treating internal cavities Apr. 08, 2025
-
Patent Title: Immunomodulating treatments of body cavities Apr. 01, 2025
-
Patent Title: Material and method for treating cancer Dec. 24, 2024
-
Patent Title: Connectable catheter May. 04, 2021
-
Patent Title: Immunomodulating treatments of body cavities Sep. 01, 2020
-
Patent Title: Material and method for treating internal cavities Nov. 12, 2019
-
Patent Title: Material and method for treating internal cavities Aug. 07, 2018
-
Patent Title: Material and method for treating internal cavities Apr. 24, 2018
-
Patent Title: Methods for treatment of bladder cancer Feb. 06, 2018
-
Patent Title: Slow release formulations of cell cycle regulators and anti-cancer agents for local treatment of solid cancer Oct. 31, 2017
-
Patent Title: Phospholipid drug analogs Jan. 10, 2017
Federal grants, loans, and purchases
- $0 2026-02-09 00:00:00 Agency: Department of Veterans Affairs
- $32,844 2025-12-09 00:00:00 Agency: Department of Veterans Affairs
- $102,264 2025-04-24 00:00:00 Agency: Department of Veterans Affairs
- $98,856 2025-02-12 00:00:00 Agency: Department of Veterans Affairs
- $98,856 2024-04-01 00:00:00 Agency: Department of Veterans Affairs
- $98,856 2024-03-21 00:00:00 Agency: Department of Veterans Affairs
- $97,430 2023-06-22 00:00:00 Agency: Department of Veterans Affairs
- $194,860 2023-06-09 00:00:00 Agency: Department of Veterans Affairs
- $97,430 2023-06-07 00:00:00 Agency: Department of Veterans Affairs
Estimated quarterly amount awarded to URGN from public contracts
Recent insights relating to URGN
Recent picks made for URGN stock on CNBC
ETFs with the largest estimated holdings in URGN
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $URGN stock a Buy, Sell, or Hold?
- What is the price target for $URGN stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $URGN stock?
- Who owns the most shares of $URGN stock?
- What funds own $URGN stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view URGN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
- Address Ra'Anana, L3
- Market Cap 2.0 billion
- Employees 291
- Industrial Classification Pharmaceutical Preparations
UroGen Pharma Ltd. Ordinary Shares (URGN) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for UroGen Pharma Ltd. Ordinary Shares (URGN).
Quiver Premium charts URGN's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at URGN, per a recent SEC DEF 14A filing.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|